Please assess the completion status of the following clinical trial:

Trial Title: The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet research criteria for Parkinson's Disease with Dementia (PDD)~* Males and females, ages between 55 and 100~* Able to undergo psychometric testing~* Mini-Mental State Examination ≥ 21 and Clinical Dementia Rating \< 2~* Reliable informant with frequent contact with patient~Exclusion Criteria:~* Non-English speaking, as cognitive tests will be in English~* Evidence of other neurological or psychiatric disorders which preclude diagnosis of PDD (including, but not limited to, stroke, any psychotic disorder, severe bipolar or unipolar depression, seizure disorder, or head injury with loss of consciousness) within the past year~* Concurrent treatment with any acetylcholinesterase inhibitors (including rivastigmine in pill or patch form), antipsychotic agents (excluding quetiapine in dosages of 150 mg and lower, abilify and geodon as these medications are commonly used in treatment of Parkinson's Disease (PD) psychosis and should not affect results of study), mood stabilizers (valproate or lithium) or benzodiazepines (other than temazepam or zolpidem)~* Positive urine drug screen or suspected alcohol or substance abuse within last 1 year~* Current malignancy, or any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease. If the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included~* Systolic blood pressure over 180 or less than 90 mm Hg. Diastolic blood pressure not greater than 105 or less than 50 mm Hg~* ECG is abnormal and judged to be clinically significant by the investigator~* Use of investigational drugs or participation in investigational drug studies within 30 days of screening~* Geriatric Depression Score score \> 15/30~* Hachinski score \> 4

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivastigmine Patch 9.5 cm2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).